Immunophilins: Beyond immunosuppression

Journal of Medicinal Chemistry

Volumn 41, Issue 26, 1998, Pages 5137-5143

  Hamilton, G S ^a   Steiner, J P ^a,b  

^a GUILFORD PHARMACEUTICALS INC   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHILIN; IMMUNOPHILIN; ISOMERASE; RAPAMYCIN; TACROLIMUS;

CIRCULAR DICHROISM; DRUG ACTIVITY; DRUG BINDING; ENZYME ACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; ISOMERISM; NUCLEAR MAGNETIC RESONANCE; PROTEIN FOLDING; PROTEIN ISOLATION; REVIEW; SEQUENCE HOMOLOGY; SPECTROPHOTOMETRY;

ANIMALS; BINDING SITES; CYCLOSPORINE; HUMANS; IMMUNOPHILINS; IMMUNOSUPPRESSIVE AGENTS; MOLECULAR CONFORMATION; NERVE REGENERATION; NERVOUS SYSTEM; PROTEIN CONFORMATION; SIROLIMUS; TACROLIMUS; TACROLIMUS BINDING PROTEINS;

EID: 0032542346     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980307x     Document Type: Article

References (245)

1. Fischer, G.; Bang, H.; Mech, C. Detection of enzyme catalysis for cis-trans isomerization of peptide bonds using proline containing peptides as substrates. Biomed. Biochim. Acta 1984, 43, 1101-1112.
2. Fischer, G.; Bang, II. The refolding of urea-denatured ribonuclease A is catalyzed by peptidyl-prolyl cis-trans isomerase. Biochim. Biophys. Acta 1984, 828, 39-42.
3. Handschumacher, R. E.; Harding, M. W.; Rice, J.; Drugge, R. J.; Speicher, D. W. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science 1984, 226, 544-546.
4. Fischer, G.; Wittmann-Liebold, B.; Lang, K.; Kiefhaber, T.; Schmid, F. X. Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature 1989, 337, 476-478.
5. Takahashi, N.; Hayano, T.; Suzuki, M. Peptidyl-prolyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin. Nature 1989, 337, 473-475.
6. Harding, M. W.; Galat, A.; Uehling, D. E.; Schreiber, S. L. A receptor for the immuno-suppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature 1989, 341, 761-763.
7. Siekerka, J. J.; Hung, S. H. Y.; Poe, M.; Lin, S. C.; Sigal, N. H. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature 1989, 341, 755-757.
8. Schreiber, S. L. Chemistry and biology of the immunophilins andtheir immunosuppressant ligands. Science 1991, 257, 283-287.
9. Galat, A. Peptidylproline cis-trans isomerases: immunophilins. Eur. J. Biochem. 1993, 276, 689-707.
10. Kay, J. E. Structure-function relationships in the FK506binding protein (FKBP) family of peptidylprolyl cis-trans isomerases. Biochem. J. 1996, 314, 361-385.
11. Rahfeld, J.-U.; Rucknagel, K. P.; Schelbert, B.; Ludwig, B.; Hacker, J.; Mann, K.; Fischer, G. Confirmation of the existence of a third family among peptidyl-prolyl cis/trans isomerases. Amino acid sequence andrecombinant production of parvulin. FEES Lett. 1994, 352, 180-184.
12. Rudd, K. E.; Sofia, H. J.; Koonin, E. V.; Plunkett, G.; Lazar, S.; Rouviere, P. R. A new family of peptidyl-prolyl isomerases. Trends Biochem. Sci. 1995, 20, 12-14
13. Standaert, R. F.; Galat, A.; Verdine, G. L.; Schreiber, S. L. Molecular cloning andoverexpression of the human FK506binding protein, FKBP. Nature 1990, 346, 671-674.
14. Albers, M. W.; VValsh, C. T.; Schreiber, S. L. Substrate specificity for the human rotamase FKBP: a view of FK506 and rapamycin as leucine-Uwisted amide)-proline mimics. J. Org. Chem. 1990, ' 55, 4984-4986.
15. Sewell, T.; Lam, E.; Martin, M.; Leszyk, J.; Weidner, J.; Calaycay, J.; Griffin, P.; Williams, H.; Hung, S.; Cryan, J.; Sigal, N.; Wiederrecht, G. Inhibition of calcineurin by a novel FK-506binding protein. J. Biol. Chem. 1994, 269, 21094-21102.
16. Lam, E.; Martin, M. M.; Timerman, A. P.; Sabers, C.; Fleischer, S.; Lukas, T.; Abraham, R. T.; O'Keefe, S. J.; O'Neill, E. A.; Weiderrecht, G. J. A novel FK506 binding protein can mediate the immunosuppressive effects of FK506 and is associated with the cardiac ryanodine receptor. J. Biol. Chem. 1995, 270, 26511-26522.
17. Jin, Y.-J.; Albers, M. W.; Lane, W. S.; Bierer, B. E.; Schreiber, S. L.; Burakoff, S. J. Molecular cloning of a membrane-associated human FK506- andrapamycin-binding protein, FKBP-13. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 6677-6681.
18. Jin, Y.-J.; Burakoff, S. J.; Bicrer, B. E. Molecular cloning of a 25-kDa high affinity rapamycin binding protein, FKBP25. J. Biol. Chem. 1992, 267, 10942-10945.
19. Galat, A.; Lane, W. S.; Standaert, R. F.; Schreiber, S. L. A rapamycin-sensitive 25-kDa immunophilin. Biochemistry 1992, 31, 2427-2434.
20. Murthy, J. N.; Goodyear, N.; Soldin, S. J. Identification of a 37 kDa tacrolimus, sirolimus and cyclosprine binding immunophilin possessing glyceraldehyde 3-phosphate dehydrogenase activity isolated from the Jurkat T cell line. Clin. Biochem. 1997, 30, 129-133.
21. Peattie, D. A.; Harding, M. W.; Fleming, M. A.; DeCenzo, M. T.; Lippke, J. A.; Livingston, D. J.; Benasutti, M. Expression and characterization of human FKBP52, an immunophilin that associates with the 90-kDa heat shock protein and is a component of steroid receptor complex. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 10974-10978.
22. Lebeau, M.-C.; Massol, N.; Herrick, J.; Faber, L. E.; Renoir, J.M.; Radanyi, C.; Baulieu, E.-E. P59, an hsp90-binding protein. Cloning and sequencing of its cDNA andpreparation of a peptide-derived polyclonal antibody. J. Biol. Chem. 1992, 267, 4281-4284.
23. Yem, A. W.; Tommasselli, A. G.; Heinrikson, R. L.; ZurcherNeely, H.; Ruff, V. A.; Johnson, D. A.; Deibel, M. R. The hsp56 component of steroid receptor complexes binds to immobilized FK-506 andshows homology to FKBP-12 andFKBP-13. J. Biol. Chem. 1992, 267, 2868-2871.
24. Harding, M. W.; Handschumacher, R. E.; Speicher, D. W. Isolation andamino acid sequence of cyclophilin. J. Biol. Chem. 1986, 267, 8547-8555.
25. Price, E. R.; Zydowsky, L. D.; Jin, M.; Baker, C. H.; McKeonand, F. D.; Walsh, C. T. Human cyclophilin B. A second cyclophilin gene encodes a peptidyl-prolyl isomeraso with a signal sequence. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 1903-1907.
26. Schneider, H.; Charara, N.; Schmilz, R.; Wehrli, S.; Mikol, V.; Zurini, M. G.; Quesniaux, V. F.; Mowa, N. R. Human cyclophilin C: primary structure, tissue distribution, and determination of binding specificity for cyclosporins. Biochemistry 1994, 33, 8218-8224.
27. Gönnern, C. P.; Halestrap, A. P. Purification and N-terminal sequencing of peptidyl-prolyl-cis-trans-isomerase from rat liver mitochondrial matrix reveals the existence of a distinct mitochondrial cyclophilin. Biochem. J. 1992, 284, 381-385.
28. Kieffer, L. J.; Thalhammer, T.; Handschumacher, R. E. Isolation and characterization of a 40-kDa cyclophilin-related protein. J. Biol. Chem. 1992, 267, 5503-5507.
29. Anderson, S. K.; Gallinger, S.; Roder, J.; Frey, J.; Young, H. A.; Ortaldo, J. R. A cyclophilin-related protein involved in the function of natural killer cells. Proc. Natl. Acad. Sci. U.SA. 1993, 90, 542-546.
30. Kofron, J. L.; Kuzmic, P.; Kishore, V.; Bonilla-Colon, E.; Rich, D. H. Determination of kinetic constants for peptidyl-prolyl cistrans isomerases by an improved spectrophotometric assay. Biochemistry 1991, 30, 6127-6134.
31. Kofron, J. L.; Kuzmic, P.; Kishore, V.; Gemmecker, G.; Fesik, S. W.; Rich, D. H. Lithium chloride perturbation of cis-trans peptide bond equilibria: effect on conformation equilibrium in cyclosporin A and on time-dependent inhibition of cyclophilin. J. Am. Chem. Soc. 1992, 114, 2670-2675.
32. Harrison, R. K.; Stein, R. L. Substrate specificities of the peptidyl-prolyl cis-trans isomerase activities of cyclophilin andFK506-binding protein: evidence for the existence of a family of distinct enzymes. Biochemistry 1990, 29, 3813-3816.
33. Lang, K.; Schmid, F. X.; Fischer, G. Catalysis of protein folding by prolyl isomerases. Nature 1987, 329, 268-270.
34. Mucke, M.; Schmid, F. X. Enzymatic catalysis of prolyl isomerization in unfolding protein. Biochemistry 1992, 31, 7848-7854.
35. Schonbrunner, E. R.; Mayer, S.; Tropschug, M.; Fischer, G.; Takahashi, N.; Schmid, F. X. Catalysis of protein folding by cyclophilins from different sources. J. Biol. Chem. 1991, 266, 3630-3635.
36. Hsu, V. L.; Handschumacher, R. E.; Armitage, I. A. Peptidylprolyl cis-trans isomerase activity of cyclophilin studied by onedimensional ]H nuclear magnetic resonance spectroscopy. J. Am. Chem. Soc. 1990, 112, 6745-6747.
37. Justice, R. M.; Mine, A. D.; Sluka, J. P.; Roeder, W. D.; Rodgers, G. H.; Roehm, N.; Mynderse, J. S. The detection of proline isomerase activity in FK506-binding protein by two-dimension 'H NMR exchange spectroscopy. Biochem. Biophys. Res. Commun. 1990, 171, 445-450.
38. Michnik, S. W.; Rosen, M. K.; Wandless, T. J.; Karplus, M.; Schreiber, S. L. Solution structure of FKBP, a rotamase enzyme andreceptor for FK506 andrapamycin. Science 1991, 252, 836-839.
39. Moore, J. M.; Peattie, D. A.; Fitzgibbon, M. J.; Thomson, J. A. Solution structure of the major binding protein for the immunosuppressant FK506. Nature 1991, 351, 248-250.
40. Ke, H.; Zydowsky, L. D.; Liu, J.; Walsh, C. T. Crystal structure of recombinant human T-cell cyclophilin A at 2.5 Å resolution. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 9483.
41. Ke, H. Similarities and differences between human cyclophilin A and other β-barrel structures. Structural refinement at 1.63 Å resolution. J. Mol. Biol. 1992, 228, 539-550.
42. Van Duyne, G. D.; Standaert, R. F.; Karplus, P. A.; Schreiber, S. L.; Clardy, J. Atomic structure of FKBP-FK506, an immunophilin-immunosuppressant complex. Science 1991, 252, 839-842.
43. Lepre, C. A.; Thomson, J. A.; Moore, J. M. Solution structure of FK506 bound to FKBP-12. FEBS Lett. 1992, 302, 89-96.
44. Van Duyne, G. D.; Standaert, R. F.; Karplus, P. A.; Schreiber, S. L.; Clardy, J. Atomic structures of the human immunophilin FKBP-12 complexes with FK506 andrapamycin. J. Mol. Biol. 1993, 229, 105-124.
45. Meadows, R. P.; Nettesheim, D. G.; Xu, R. X.; Olejniczak, E. T.; Petros, A. M.; Holzman, T. F.; Severin, J.; Gubbins, E.; Smith, H.; Fesik, S. W. Three-dimensional structure of the FK506 binding protein/ascomycin complex in solution by heteronuclear three- andfour-dimensional NMR. Biochemistry 1993, 32, 754-765.
46. Van Duyne, G. D.; Standaert, R. F.; Karplus, P. A.; Schreiber, S. L.; Clardy, J. Atomic structures of the human immunophilin FKBP-12 complexes with FK506 andrapamycin. J. Mol. Biol. 1993, 229, 105-124.
47. Wilson, K. P.; Yamashita, M. M.; Sintchak, M. D.; Rotstein, S. H.; Murcko, M. A.; Boger, J.; Thomson, J. A.; Fitzgibbon, M. J.; Black, J. R.; Navia, M. A. Comparative X-ray structures of the major binding protein for the immunosuppressant FK506 (Tacrolimus) in unliganded form andin complex with FK506 andrapamycin. Acta Crystallogr. 1995, D51, 511-521.
48. Becker, J. W.; Rotonda, J.; McKeever, B. M.; Chan, H. K.; Marcy, A. L; Wiederrecht, G.; Hermes, J. D.; Springer, J. P. FK-506binding protein: three-dimensional structure of the complex with the antagonist L-685, 818. J. Biol. Chem. 1993, 268, 11335-11339.
49. Holt, D. A.; Luengo, J. I.; Yamashita, D. S.; Oh, H.-J.; Konialian, A. L.; Yen, H.-K; Rozamus, L. W.; Brandt, M.; Bossard, M. J.; Levy, M. A.; Eggleston, D. S.; Liang, J.; Schultz, L. W.; Stout, T. J.; Clardy, J. Design, synthesis, andkinetic evaluation of highaffinity FKBP ligands and the X-ray crystal structures of their complexes with FKBP12. J. Am. Chem. Soc. 1993, 115, 9925-9938.
50. Armistead, D. M.; Badia, M. C.; Deininger, D. D.; Duffy, J. P.; Saunders, J. O.; Tung, R. D.; Thomson, J. A.; DeCenzo, M. T.; Futer, O.; Livingston, D. J.; Murcko, M. A.; Yamashita, M. M.; Navia, M. A. Design, synthesis andstructure of nonmacrocyclic inhibitors of FKBP12, the major binding protein for the immunosuppressant FK506. Acta Crystallogr. 1995, D51, 522-528.
51. Liu, J.; Albers, M. W.; Chen, C. M.; Schreiber, S. L.; Walsh, C. T. Cloning, expression, and purification of human cyclophilin in Escherichia coli and assessment of the catalytic role of cysteines by site-directed mutagenesis. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 2304-2308.
52. Harrison, R. K.; Stein, R. L. Mechanistic studies of peptidyl prolyl cis-trans isomerase: evidence for catalysis by distortion. Biochemistry 1990, 29, 1684-1689.
53. Rosen, M. K.; Standaert, R. F.; Galat, A.; Nakatsuka, M.; Schreiber, S. L. Inhibition of FKBP rotamase activity by immunosuppressant FK506: twisted amide surrogate. Science 1990, 248, 863-866.
54. Orozco, M.; Tirado-Rives, J.; Jorgensen, W. L. Mechanism for the rotamase activity of FK506 binding protein from molecular dynamics simulations. Biochemistry 1993, 32, 12864-12874.
55. Fischer, S.; Michnik, S.; Karplus, M. A mechanism for rotamase catalysis by the FK506 binding protein. Biochemistry 1993, 32, 13830-13837.
56. Wiederrecht, G.; Hung, S.; Chan, H. K.; Marcy, A.; Martin, M.; Calaycay, J.; Boulton, D.; Sigal, N.; Kincaid, R. L.; Siekierka, J. J. Characterization of high molecular weight FK-506 binding activities reveals a novel FK-506-binding protein as well as a protein complex. J. Biol. Chem. 1992, 267, 21753-21760.
57. Bossard, M. J.; Bergsma, D. J.; Brandt, M.; Livi, G. P.; Eng, W.K; Johnson, R. K.; Levy, M. A. Catalytic and ligand binding properties of the FK506 binding protein FKBP12: effects of the single amino acid substitution of Tyr82 to Leu. Biochem. J. 1994, 297, 365-372.
58. DeCenzo, M. T.; Park, S. T.; Jarrett, B. P.; Aldape, R. A.; Futer, O.; Murcko, M. A.; Livingston, D. J. FK506-binding protein mutational analysis: defining the active-site residue contributions to catalysis andthe stability of ligand complexes. Protein Eng. 1996, 9, 173-180.
59. Aldape, R. A.; Futer, O.; DeCenzo, M. T.; Jarrett, B. P.; Murcko, M. A.; Livingston, D. J. Charged surface residues of FKBP12 participate in formation of the FKBP12-FK506-calcineurin complex. J. Biol. Chem. 1992, 267, 16029-16032.
60. Timerman, A. P.; Wiederrecht, G.; Marcy, A.; Fleischer, S. Characterization of an exchange reaction between soluble FKBP-12 and the FKBP-ryanodine receptor complex. Modulation by FKBP mutants deficient in peptidyl-prolyl isomerase activity. J. Biol. Chem. 1995, 270, 2451-2459.
61. Nigam, S. K; Jin, Y.-J.; Jin, M. J.; Bush, K. T.; Bierer, B. E.; Burakoff, S. J. Localization of the FK506-binding protein, FKBP 13, to the lumen of the endoplasmic reticulum. Biochem. J. 1993, 294, 511-515.
62. Bush, K. T.; Hendrickson, B. A.; Nigam, S. K. Induction of the FK506-binding protein, FKBP13, under conditions which misfold proteins in the endoplasmic reticulum. Biochem. J. 1994, 303, 705-708.
63. Schultz, L. W.; Martin, P. K.; Liang, J.; Schreiber, S. L.; Clardy, J. Atomic structure of the immunophilin FKBP13-FK506 complex: insights into the composite binding surface for calcineurin. J. Am. Chem. Soc. 1994, 116, 3129-3130.
64. Riviere, S.; Menez, A.; Galat, A. On the localization of FKBP25 in T-Iymphocytes. FEBS Lett. 1993, 375, 247-251.
65. Jin, Y. J.; Burakoff, S. J. The 25-kDa FK506-binding protein is localized in the nucleus and associates with casein kinase II andnucleolin. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 7769-7773.
66. Fretz, H.; Albers, M. A.; Galat, A.; Standaert, R. F.; Lane, W. S.; Burakoff, S. J.; Bierer, B. E.; Schreiber, S. L. Rapamycin and FK506 binding proteins (immunophilins). J. Am. Chem. Soc. 1991, 113, 1409-1410.
67. Tai, P. K.-K.; Albers, M. A.; Chang, H.; Faber, L. E.; Schreiber, S. L. Association of a 59-kilodalton immunophilin with the glucocorticoid receptor complex. Science 1992, 256, 1315-1318.
68. Callebaut, L.; Renoir, J.-M.; Lebeau, M.-C.; Massol, N.; Burny, R.; Baulieu, E.-E.; Mornon, J.-P. An immunophilin that binds Mr 90000 heat shock protein: structural features of a mammalian p59 protein. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 6270-6274.
69. Chambraud, B.; Rouviere-Fourmy, N.; Radanyl, C.; Hsiao, K.; Peattie, D. A.; Livingston, D. J.; Baulieu, E.-E. Overexpression of p59-HBI (FKBP59), full length and domains, and characterization of PPlase activity. Biochem. Biophys. Res. Commun. 1993, 196, 160-166.
70. Donnelly, J. G.; Soldin, S. J. Partial characterization of a 52 kDa CsA/FK506/rapamycin binding protein. Clin. Biochem. 1994, 27, 367-372.
71. Weber, C.; Wider, G.; Von Freyburg, B.; Traber, R.; Braun, W.; Widmer, H.; Wüthrich, K The NMR structure of cyclosporin A bound to cyclophilin in aqueous solution. Biochemistry 1991, 30, 6563-6574.
72. Theriault, Y.; Logan, T. M.; Meadows, R.; Yu, L.; Olejniczak, E. T.; Holzman, T. F.; Simmer, R. L.; Fesik, S. W. Solution structure of the cyclosporin A/cyclophilin complex by NMR. Nature 1993, 367, 88-91.
73. Pfluegl, G.; Kallen, J.; Schirmer, T.; Jansonius, J. N.; Zurini, M. G.; Walkinshaw, M. D. X-ray structure of a decameric cyclophilin-cyclosporin crystal complex. Nature 1993, 367, 9194.
74. Mikol, V.; Kallen, J.; Pfluegl, G.; Walkinshaw, M. D. X-ray structure of monomeric cyclophilin A-cyclosporin A crystal complex at 2.1 Aresolution. J. Mol. Biol. 1993, 234, 1119-1130.
75. Spitzfaden, C.; Braun, W.; Wider, G.; Widmer, H.; Wüthrich, K. Determination of the NMR solution structure of the cyclophilincyclosporin A complex. J. Biomol. NMR 1994, 4, 463-482.
76. Kallen, J.; Walkinshaw, M. D. The X-ray structure of a tetrapeptide bound to the active site of human cyclophilin A. FEBS Lett. 1992, 300, 286-290.
77. Ke, H.; Mayrose, D.; Cao, W. Crystal structure of cyclophilin A complexed with substrate Ala-Pro suggests a solvent-assisted mechanism of cis-trans isomerization. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 3324-3328.
78. Zhao, Y.; Ke, H. Mechanistic implication of crystal structures of the cyclophilin-dipeptide complexes. Biochemistry 1996, 35, 7362-7368.
79. Zhao, Y.; Ke, H. Crystal structure implies that cyclophilin predominately castalyzes the trans to cis isomerization. Biochemistry 1996, 35, 7356-7361.
80. Braun, W.; Kallen, J.; Mikol, V.; Walkinshaw, M. D.; Wüthrich, K. Three-dimensional structure andactions of immunosuppressants andtheir immunophilins. FASEB J. 1995, 9, 63-72.
81. Loosli, H.; Kessler, H.; Oschkinat, H.; Weber, H.; Petcher, T. J.; Widmer, A. The conformation of cyclosporin A in the crystal andin solution. Helv. Chim. Ada 1995, 68, 682-704.
82. Kessler, H.; Gehrke, M.; Lautz, J.; Koeck, M.; Seebach, D.; Thaler, A. Complexation and medium effects on the conformation of cyclosporin A studied by NMR spectroscopy and molecular dynamics calculations. Biochem. Pharmacol. 1990, 40, 169-173.
83. Mikol, V.; Kallen, J.; Walkinshaw, M. D. X-ray structure of a cyclophilin B/cyclosporin complex: Comparison with cyclophilin A anddelineation of its calcineurin-binding domain. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 5183-5186.
84. Etzkorn, F. A.; Chang, Z. Y.; Stolz, L. A.; Walsh, C. T. Cyclophilin residues that affect noncompetitive inhibition of the protein serine phosphatase activity of calcineurin by the cyclophilincyclosporin A complex. Biochemistry 1994, 33, 2380-2388.
85. Friedman, J.; Weissman, I. Two cytoplasmic candidates for immunophilin action are revealed by affinity for a new cyclophilin: one in the presence andone in the absence of CsA. Cell 1991, 66, 799-806.
86. Ke, H.; Zhao, Y.; Luo, F.; Weissman, I.; Friedman, J. Crystal structure of murine cyclophilin C complexed with immunosuppressant drug cyclosporin A. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 11850-11854.
87. Friedman, J.; Trahey, M.; Weissman, I. Cloning and characterization of cyclophilin C-associated protein: a candidate natural cellular ligand for cyclophilin C. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 6815-6819.
88. Bergsma, D. J.; Eder, C.; Gross, M.; Kerster, H.; Sylvester, D.; Appelbaum, E.; Cusimano, D.; Livi, G. P.; McLaughlin, M. M.; Kasyan, K.; Porter, T. G.; Silverman, C.; Dunnington, D.; Hand, A.; Prichett, W. P.; Bossard, M. J.; Brandt, M.; Levy, M. A. The cyclophilin multigene family of peptidyl-prolyl isomerases. Characterization of three separate human isoforms. J. Biol. Chem. 1991, 266, 23204-23214.
89. Woodfield, K. Y.; Price, N. T.; Halestrap, A. P. cDNA cloning of rat mitochondria! cyclophilin. Biochim. Biophys. Ada 1997, 1351, 27-30.
90. Tanveer, A.; Virji, S.; Andreeva, L.; Totty, N. F.; Hsuan, J. J.; Ward, J. M.; Crompton, M. Involvement of cyclophilin D in the activation of a mitochondrial pore by Ca24" and oxidant stress. Eur. J. Biochem. 1996, 238, 166-172.
91. Kieffer, L.; Seng, T. W.; Li, W.; Osterman, D. G.; Handschumacher, R. E.; Bayney, R. M. Cyclophilin-40, a protein with homology to the p59 component of the steroid receptor complex. J. Biol. Chem. 1993, 268, 12303-12310.
92. Ratajczak, T.; Carrello, A.; Mark, P. J.; Wamer, B. J.; Simpson, R. J.; Moritz, R. L.; House, A. K. The cyclophilin component of the unactivated estrogen receptor contains a tetratricopeptide repeat domain andshares identity with p59 (FKBP59). J. Biol. Chem. 1993, 268, 13187-13192.
93. Hoffmann, K.; Kakalis, L. T.; Anderson, K. S.; Armitage, I. A.; Handschumacher, R. E. Expression of human cyclophilin-40 andthe effect of the Hisl41-Trp mutation on catalysis and cyclosporin A binding. Eur. J. Biochem. 1995, 229, 188-193.
94. Liu, J.; Chen, C.-M.; Walsh, C. T. Human and Escherichia coli cyclophilins: sensitivity to inhibition by the immunosuppressant cyclosporin A correlates with a specific tryptophan residue. Biochemistry 1991, 30, 2306-2310.
95. Anderson, S. K.; Gallinger, S.; Roder, J.; Frey, J.; Young, H. A.; Ortaldo, J. R. A cyclophilin-related protein involved in the function of natural killer cells. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 542-546.
96. Rosen, M. K; Schreiber, S. L. Natural products as probes of cellular function: studies of immunophilins. Aneiu. Chem., Int. Ed. Eng. 1992, 31, 384-400.
97. Armistead, D. M.; Harding, M. W. Immunophilins and immunosuppressive drug action. Annu. Rep. Med. Chem. 1993, 28, 207-215.
98. Bierer, B. E.; Mattila, P. S.; Standaert, R. F.; Herzenberg, L. A.; Burakoff, S. J.; Crabtree, G.; Schreiber, S. L. Two distinct signal transmission pathways are inhibited in T-lymphocytes by complexes formed between an immunophilin andeither FK506 or rapamycin. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 9231-9235.
99. Dumont, F. J.; Melino, M. R.; Staruch, M. J.; Koprak, S. L.; Fisher, P. A.; Sigal, N. H. The immunosuppressive macrolides FK-506 andrapamycin act as reciprocal antagonists in murine T-cells. J. Immunol. 1990, 144, 1418-1424.
100. Somers, P. K.; Wandless, T. J.; Schreiber, S. L. Synthesis and analysis of 506BD, a high-affinity ligand for the immunophilin FKBP. J. Am. Chem. Soc. 1991, 113, 8045-8056.
101. Bierer, B. E.; Somers, P. K.; Wandless, T. J.; Burakoff, S. J.; Schreiber, S. L. Probing immunosuppressant action with a nonnatural immunophilin ligand. Science 1990, 250, 556-559.
102. Dumont, F. J.; Staruch, M. J.; Koprak, S. L.; Siekerka, J. J.; Lin, C. S.; Harrison, R.; Sewell, T.; Kindt, V.; Beattie, T. R.; Wyvratt, M.; Sigal, N. H. The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin. J. Exp. Med. 1992, 176, 751-760.
103. Sigal, N. H.; Dumont, F.; Durette, P.; Siekerka, J. J.; Peterson, L.; Rich, D. H.; Dunlap, B. E.; Staruch, M. J.; Melino, M. R.; Koprak, S. L.; Williams, D.; Witzel, B.; Pisano, J. M. Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclosporin A? J. Exp. Med. 1991, 173, 619-628.
104. Ocain, T. D.; Longhi, D.; Steffan, R. J.; Caccese, R. G.; Sehgal, S. N. A nonimmunosuppressive trienc-modified rapamycin analogue is a potent inhibitor of peptidyl prolyl cis-trans isomerasc. Biochem. Biophys. Res. Commun. 1993, 192, 1340-1346.
105. Liu, J. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991, 66, 807-815.
106. Clipston, N. A.; Crabtree, G. R. Identification of calcineurin as a key signaling enzyme in T-lymphocyte activation. Nature 1992, 357, 695-697.
107. O'Keefe, S. J.; Tamura, J.; Kincaid, R. F.; Tocci, M. J.; O'Neill, M. A. FK-506- and CsA-sensitive activation of the interleukiri-2 promoter by calcineurin. Nature 1992, 357, 692-694.
108. Flanagan, W. M.; Corthesy, B.; Bram, R. J.; Crabtree, G. R. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature 1991, 352, 754-755.
109. Kuo, C. J.; Chung, J.; Florentino, D. F.; Flanagan, W. M.; Blenis, J.; Crabtree, G. R. Rapamycin selectively inhibits interleukin-2 inhibition of p70 S6 kinase. Nature 1992, 358, 70-73.
110. Chung, J.; Kuo, C. J.; Crabtree, G. R.; Blenis, J. RapamycinFKBP specifically blocks growth dependent activation of and signaling by the 70 kd S6 protein kinases. Cell 1992, 69, 1227-1236.
111. Price, D. J.; Grove, J. R.; Calvo, V.; Avruch, J.; Bierer, B. E. Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science 1992, 257, 973-977.
112. Jayaraman, T.; Marks, A. R. Rapamycin-FKBP12 blocks proliferation, induces differentiation, andinhibits cdc2 kinase activity in a myogenic cell line. J. Biol. Chem. 1993, 268, 25385-25388.
113. Morice, W. G.; Wiederrecht, G.; Brunn, G. J.; Siekerka, J. J.; Abraham, R. T. Rapamycin inhibition of interleukin-2-dependent p33cdk2 andp34cdc2 kinase activition in T lymphocytes. J. Biol. Chem. 1993, 268, 22737-22745.
114. Kunz, J.; Henriquez, R.; Schneider, U.; Deuter-Reinhard, M.; Mowa, N. R.; Hall, M. N. Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homologue required for Gl progression. Cell 1993, 73, 585-596.
115. Sabatini, D. M.; Erdjument-Bromage, H.; Lui, M.; Tempst, P.; Snyder, S. H. RAFT1 (rapamycin andFKBP12 target): a mammalian protein that binds to FKBP12 in rapamycindependent fashion andis homologous to yeast TORs. Cell 1994, 78, 35-43.
116. Brown, E. J.; Albers, M. W.; Shin, T. B.; Ichikawa, K.; Keith, C. T.; Lane, W. S.; Schreiber, S. L. A mammalian protein targeted by Gl-arresting rapamycin-receptor complex. Nature 1994, 369, 756-758.
117. Brown, E. J.; Beal, P. A.; Keith, C. T.; Chen, J.; Shin, T. B.; Schreiber, S. L. Control of p70 S6 kinase by kinase activity of FRAP in vivo. Nature 1995, 377, 441-446.
118. Beretta, L.; Gingras, A.-C.; Svitkin, Y. V.; Hall, M.; Sonenberg, N. Rapamycin blocks the phosphorylation of 4E-BP1 andinhibits cap-dependent initiation of translation. EMBO J. 1996, 15, 658-664.
119. Chou, M. M.; Blenis, J. The 70 kDa S6 kinase: regulation of a kinase with multiple roles in mitogenic signaling. Curr. Opin. Cell Biol. 1995, 7, 806-814.
120. Brown, E. J.; Schreiber, S. L. A signaling pathway to translational control. Cell 1996, 86, 517-520.
121. Schmid, F. X.; Mayr, L.; Mucke, M.; Schonbrunner, E. R. Prolyl isomerases: the role in protein folding. Adv. Protein Chem. 1993, 44, 25-66.
122. Lilie, H.; Rudolph, R.; Buchner, J. Association of antibody chains at different stages of folding: prolyl isomerization occurs after formation of quaternary structure. J. Mol. Biol. 1995, 248, 190-201.
123. Freskgard, P.-O.; Bergenhem, N.; Jonsson, B.-H.; Svensson, M.; Carlson, U. Isomerase andchaperone activity of prolyl isomerase in the folding of carbonic anhydrase. Science 1992, 258, 466-468.
124. Kiefhaber, T.; Quass, R.; Hahn, U.; Schmid, F. X. Folding of ribonuclease Tl. 2. Kinetic models for the refolding andunfolding reactions. Biochemistry 1990, 29, 3061-3070.
125. London, R. E.; Davis, D. G.; Vavrek, R. J.; Stewart, J. M.; Handschumacher, R. E. Bradykinin andits Gly6 analogue are substrates of cyclophilin: a fluorine-19 magnetization transfer study. Biochemistry 1990, 29, 10298-10302.
126. Kern, D.; Drakenberg, T.; Wilkstrom, M.; Forsen, S.; Bang, H.; Fischer, G. The cis/trans interconversion of the calcium regulating hormone calcitonin is catalyzed by cyclophilin. FEBS Lett. 1993, 323, 198-202.
127. Kern, G.; Kern, D.; Schmid, F. X.; Fischer, G. Reassessment of the putative chaperone function of prolyl-cis/trans-isomerases. FEBS Lett. 1994, 348, 145-148.
128. Tropschug, M.; Wächter, E.; Mayer, S.; Schonbrunner, E. R.; Schmid, F. X. Isolation andsequence of an FK506-binding protein from N. crassa which catalyzes protein folding. Nature 1990, 343, 674-677.
129. Colley, N. J.; Baker, E. K.; Stamnes, M. A.; Zuker, C. S. The cyclophilin homologue ninaA is required in the secretory pathway. Cell 1991, 67, 255-263.
130. Ondek, B.; Hardy, R. W.; Baker, E. K.; Stamnes, M. A.; Shieh, B.-H.; Zuker, C. S. Genetic dissection of cyclophilin function. Saturation mutagenesis of the Drosophila cyclophilin homologue ninaA. J. Biol. Chem. 1992, 267, 16460-16466.
131. Ferreira, P. A.; Nakayama, T. A.; Pak, W. L.; Travis, G. H. Cyclophilin-related protein RanBP2 acts as chaperone for red/ green opsin. Nature 1996, 383, 637-640.
132. Lodish, H. F.; Kong, N. Cyclosporin A inhibits an initial step in folding of transferrin within the endoplasmic reticulum. J. Biol. Chem. 1991, 266, 14835-14838.
133. Steinmann, B.; Bruckner, P.; Furga-Supereti, A. Cyclosporin A slows collagen triple-helix formation in vivo: indirect évidence for a physiologie role of peptidyl-prolyl cis-trans isomerase. J. Biol. Chem. 1991, 266, 1299-1303.
134. Helekar, S. A.; Char, D.; Neff, S.; Patrick, J. Prolyl isomerase requirement for thé expression of functional homooligomeric ligand-gated ion channels. Neuron 1994, 12, 179-189.
135. Callebaut, L; Mornon, J. P. Trigger factor, one of the Escherichia coll chaperone proteins, is an original member of the FKBP family. FEBS Lett. 1995, 374, 211-215.
136. Ratajczak, T.; Carrello, A.; Mark, P. J.; Warner, B. J.; Simpson, R. J.; Moritz, R. L.; House, A. K. The cyclophilin component of the unactivated estrogen receptor contains a tetratricopeptide repeat domain and shares identity with p59 (FKBP59). J. Biol. Chem. 1993.26S, 13187-13192.
137. Ku, P.-K.; Albers, M. A.; Chang, H.; Faber, L. E.; Schreiber, S. L. Association of a 59-kiIodalton immunophilin with the glucocorticoid receptor complex. Science 1992, 256, 1315-1318.
138. Owens-Grillo, J. K.; Hoffmann, K.; Hutchison, K. A.; Yem, A. W.; Deibel, M. R.; Handschumacher, R. E.; Pratt, W. B. The Cyclosporin A-binding immunophilin CyP-40 andthe FK506binding immunophilin hsp56 bind to a common site on hsp90 andexist in independent cytosolic heterocomplexes with the untransformed glucocorticoid receptor. J. Biol. Chem. 1995, 270, 20479-20484.
139. Duina, A. A.; Chang, H.-C. J.; Marsh, J. A.; Lindquist, S.; Gaber, R. F. A cyclophilin function in hsp90-dependent sugnal transduction. Science 1996, 274, 1713-1715.
140. Freeman, B. C.; Toft, D. O.; Morimoto, R. I. Molecular chaperone machines: chaperone activities of the cyclophilin Cyp-40 andthe steroid aporeceptor-associated protein p23. Science 1996, 274, 1718-1720.
141. Böse, S.; Weikl, T.; Bugl, H.; Buchner, J. Chaperone function of hsp90-associated proteins. Science 1996, 274, 1715-1718.
142. Fleischer, S.; Inui, M. Biochemistry andbiophysics of excitationcontraction coupling. Annu. Rev. Biophys. Biophys. Chem. 1989, 18, 333-364.
143. Collins, J. H. Sequence analysis of the ryanodine receptor: possible association with a 12K, 506-binding immunophilin/ protein kinase C inhibitor. Biochem. Biophys. Res. Commun. 1991, 178, 1288-1290.
144. Jayraman, T.; Brillantes, A.-M.; Timerman, A. P.; Fleischer, S.; Erdjument-Bromage, H.; Tempst, P.; Marks, A. R. FK506 binding protein associated with the calcium release channel (Ryanodine receptor). J. Biol. Chem. 1992, 267, 9474-9477.
145. Brillantes, A.-M.; Ondrias, K.; Scott, A.; Kobrinsky, E.; Ondriasova, E.; Moschella, M. C.; Jayraman, T.; Landers, M.; Ehrlich, B. E.; Marks, A. R. Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein. Cell 1994, 77, 513-523.
146. Furuichi, T. Primary structure and functional expression of the inositol 1, 4, 5-triphosphate-binding protein P400. Nature 1989, 342, 32-38.
147. Berridge, M. J.; Irvine, R. F. Inositol phosphates andcell signaling. Nature 1989, 341, 197-204.
148. Ferris, C. D.; Snyder, S. H. Inositol 1, 4, 5-triphosphate activated calcium channels. Annu. Rev. Physiol. 1991, 54, 469-488.
149. Cameron, A. M.; Steiner, J. P.; Sabatini, D. M.; Kaplin, A. I.; Walensky, L. D.; Snyder, S. H. Immunophilin FK506 binding protein associated with inositol 1, 4, 5-trisphosphate receptor modulates calcium flux. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 1784-1788.
150. Cameron, A. M.; Steiner, J. P.; Roskams, A. J.; Ali, S. M.; Ronnett, G. V.; Snyder, S. H. Calcineurin associated with the inositol 1, 4, 5-triphosphate receptor-FKBP12 complex modulates Ca2t flux. Cell 1995, 83, 463-472.
151. Massague, J.; Attisano, L.; Wrana, J. L. The TGF-β family andits composite receptors. Trends Cell Biol. 1994, 4, 172-178.
152. Wang, T. W.; Donahoe, P. K.; Zervos, A. S. Specific interaction of type I receptors of the TGF-β family with the immunophilin FKBP12. Science 1994, 265, 674-676.
153. Wrana, J. L.; Attisano, L.; Weiser, R.; Ventura, F.; Massague, J. Mechanism of activation of the TGF-/I receptor. Nature 1994, 370, 341-347.
154. Wang, T.; Li, B.-Y.; Danielson, P. D.; Shah, P. C.; Rockwell, S.; Lechleider, R. J.; Martin, J.; Manganaro, T.; Donahoe, P. K. The immunophilin FKBP12 functions as a common inhibitor of the TGF- family type I receptors. Cell 1996, 86, 435-444.
155. Yang, D.; Rosen, M. K.; Schreiber, S. L. A composite FKBP12FK506 surface that contacts calcineurin. J. Am. Chem. Soc. 1993, 115, 819-820.
156. Bram, R. J.; Crabtree, G. R. Calcium signaling in T cells stimulated by a cyclophilin B-binding protein. Nature 1994, 371, 355-358.
157. Halloway, M. P.; Bram, R. J. A hydrophobic domain of Ca+2modulating cyclophilin ligand modulates calcium influx signaling in T lymphocytes. J. Biol. Chem. 1996, 277, 8549-8552.
158. Bram, R. J. Isolation of a cDNA encoding the chicken homologue of the human calcium modulating cyclophilin ligand. Gene 1996, 174, 307-309.
159. Bang, H.; Muller, Vf.; Hans, M.; Brune, K.; Swandulla, D. Activation of Ca2+ signaling in neutrophils by the mast cellreleased immunophilin FKBP12. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 3435-3438.
160. Cirillo, R.; de Paulis, A.; Ciccarelli, A.; Triggiani, M.; Marone, G. Cyclosporin A inhibits mediator release from human FcRI+ cells by interacting with cyclophilin. Int. Arch. Allergy Appl. Immunol. 1991, 94, 76-77.
161. Snyder, S. H.; Sabatini, D. M. Immunophilins and the nervous system. Nature Med. 1995, 1, 32-37.
162. Timerman, A. P.; Wiederrecht, G.; Marcy, A.; Fleischer, S. Characterization of an exchange reaction between soluble FKBP12 andthe FKBP-ryanodine receptor complex. Modulation by FKBP mutants deficient in peptidyl-prolyl isomerase activity. J. Biol. Chem. 1995, 270, 2451-2459.
163. Cameron, A. M.; Nucifora, F. C.; Fung, E. T.; Livingston, D. J.; Aldape, R. A.; Ross, C. A.; Snyder, S. H. FKBP12 binds the inositol 1, 4, 5-triphosphate teceptor at leucine-proline (1400-1401) and anchors calcineurin to the FK506-like domain. J. Biol. Chem. 1997, 272, 27582-27588.
164. Pawson, T. Protein modules andsignaling networks. Nature 1995, 373, 573-580.
165. Coghlan, V. M.; Perrino, B. A.; Howard, M.; Langeberg, L. K; Hicks, J. B.; Gallatin, W. M.; Scott, J. D. Association of protein kinase A andprotein phosphatase 2B with a common anchoring protein. Science 1995, 267, 108-111.
166. Maki, N.; Sekiguchi, F.; Nishimaki, J.; Miwa, K.; Hayano, T.; Takahashi, N.; Suzuki, M. Complementary DNA encoding the human T-cell FK506-binding protein, a peptidylprolyl cis-trans isomerase distinct from cyclophilin. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 5440-5443.
167. Steiner, J. P.; Dawson, T. M.; Fotuhi, M.; Glatt, C. E.; Snowman, A. M.; Cohen, N.; Snyder, S. H. High brain densities of the immunophilin FKBP colocalized with calcineurin. Nature 1992, 358, 584-587.
168. Dawson, T. M.; Steiner, J. P.; Lyons, W. E.; Fotuhi, M.; Blue, M.; Snyder, S. H. The immunophilin, FK506-binding protein andcyclophilin, are discretely localized in the brain: relationship to calcineurin. Neuroscience 1994, 62, 569-580.
169. Dawson, T. M.; Steiner, J. P.; Dawson, V. L.; Dinerman, J. L.; Uhl, G. R.; Snyder, S. H. Immunosuppressant, FK506, enhances phosphorylation of nitric oxide synthase andprotects against glutamate neurotoxicity. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 9808-9812.
170. Mein, K. F.; Bickerstaff, L. E.; Schwob, J. E. Monoclonal antibodies show that kinase C phosphorylation of GAP-43 during axonogenesis is both spatially andtemporally restricted in vivo. J. Cell Biol. 1991, 112, 991-1005.
171. Lyons, W. E.; Steiner, J. P.; Snyder, S. H.; Dawson, T. M. Neuronal regeneration enhances the expression of the immunophilin FKBP. J. Neurosci. 1995, 15, 2985-2994.
172. Lyons, W. E.; George, E. B.; Dawson, T. M.; Steiner, J. P.; Snyder, S. H. Immunosuppressant FK506 promotes neunte outgrowth in cultures of PC-12 cells andsensory ganglia. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 3191-3195.
173. Gold, B. G. FK506 and the role of immunophilins in neuronal regeneration. Mol. Neurobiol. 1997, 15, 285-306.
174. Chang, H. Y.; Takei, K.; Sydor, A. M.; Born, T.; Rusnak, F.; Jay, D. G. Asymmetric retraction of growth cone filopodia following focal inactivation of calcineurin. Nature 1995, 376, 686-690.
175. Gold, B. G.; Storm-Dickerson, T.; Austin, D. R. The immunosuppressant FK506 increases functional recovery andnerve regeneration following peripheral nerve injury. Restorative Neuroi. Neurosci. 1994, 6, 287.
176. Gold, B. G.; Katoh, K.; Storm-Dickerson, T. The immunosuppressant FK506 increases the rate of axonal regeneration in rat sciatic nerve. J. Neurosci. 1995, 15, 7509-7516.
177. Wang, M. S.; Zeleny-Pooley, M.; Gold, B. G. Comparative dosedependence study of FK506 andcyclosporin A on the rate of axonal regeneration in the rat sciatic nerve. J. Pharmacol. Exp. Ther. 1997, 252, 1084-1093.
178. Palmer, R. M.; Higgs, E. A. Nitric oxide: physiology, pathophysiology andpharmacology. Pharmacol. Rev. 1991, 43, 109-142.
179. Dawson, T. M.; Snyder, S. H. Gases as biological messengers: nitric oxide andcarbon monoxide in the brain. J. Neurosci. 1994, 14, 5147-5159.
180. Bredt, D. S.; Ferns, C. D.; Snyder, S. H. Nitric oxide synthase regulatory sites. J. Biol. Chem. 1992, 267, 10976-10981.
181. Bredt, D. S.; Snyder, S. H. Nitric oxide mediates glutamatelinked enhancement of cGMP levels in the cerebellum. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 9030-9033.
182. Choi, D. W. Bench to bedside: the glutamate connection. Science 1992, 258, 241-243.
183. Dawson, V. L.; Dawson, T. M.; London, E. D.; Bredt, D. S.; Snyder, S. H. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 6368-6371.
184. Dawson, V. L.; Kizushi, V. M.; Huang, P. L.; Snyder, S. H.; Dawson, T. M. Resistance to neurotoxicity in cortical cultures from neuronal nitric oxide synthase-deficient mice. J. Neurosci. 1996, 16, 2479-2487.
185. Sharkey, J.; Butcher, S. P. Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischemia. Nature 1994, 377, 336-339.
186. Tokime, T.; Nozaki, K; Kikuchi, H. Neuroprotective effect of FK506, an immunosuppressant, on transient global ischemia in gerbil. Neurosci. Lett. 1996, 206, 81-84.
187. Ide, T.; Morikawa, E.; Kirino, T. An immunosuppressant, FK506, protects hippocampal neurons from forebrain ischemia in the Mongolian gerbil. Neurosci. Lett. 1996, 204, 157-160.
188. Butcher, S. P.; Henshall, D. C.; Teramura, Y.; Iwasaki, K.; Sharkey, J. Neuroprotective actions of FK506 in experimental stroke: in vivo evidence against an anti-excitotoxic mechanism. J. Neurosci. 1997, 17, 6939-6946.
189. Yagita, Y.; Kitagawa, K.; Matsushita, K.; Taguchi, A.; Mabuchi, T.; Ohtsuki, T.; Yanagihara, T.; Matsumoto, M. Effect of immunosuppressant FK506 on ischemia-induced degeneration of hippocampal neurons in gerbils. Life Sci. 1996, 59, 1643-1650.
190. Tong, G.; Shepherd, D.; Jahr, C. E. Synaptic desensitization of NMDA receptors by calcineurin. Science 1995, 267, 1510-1512.
191. Funauchi, M.; Haruta, H.; Tsumoto, T. Effects of an inhibitor for calcium/calmodulin-dependent protein phosphatase, calcineurin, on induction of long-term potentiation in rat visual cortex. Neurosci. Res. 1994, 19, 269-278.
192. Torii, N.; Kamishita, T.; Otsu, Y.; Tsumoto, T. An inhibitor for calcineurin, FK506, blocks induction of long-term depression in rat visual cortex. Neuroscience 1995, 185, 1-4.
193. Ikegami, S.; Kato, A.; Kudo, Y.; Kuno, T.; Ozawa, F.; Inokuchi, K A facilitatory effect on the induction of long-term potentiation in vivo by the chronic administration of antisense oligonucleotides against catalytic subunits of calcineurin. Mol. Brain Res. 1996, 41, 183-191.
194. Hodgkiss, J. P.; Kelly, S. J. Only "de novo" long-term depression (LTD) in the rat hippocampus in vitro is blocked by the same low concentration of FK506 that blocks LTD in the visual cortex. Brain Res. 1995, 705, 241-246.
195. Kantor, D. B.; Lanzrein, M.; Stary, S. J.; Sandoval, G. M.; Smith, W. B.; Sullivan, B. M.; Davidson, N.; Schuman, E. M. A role for endothelial NO synthase in LTP revealed by adenovirus-mediated inhibition andrescue. Science 1996, 274, 1744-1748.
196. Schuman, E. M.; Madison, D. V. A requirement for the intercellular messenger nitric oxide in long-term potentiation. Science 1991, 254, 1503-1506.
197. O'Dell, T. J.; Hawkins, R. D.; Kandel, E. R.; Arancio, O. Tests of the roles of two diffusible substances in long-term potentiation: evidence for nitric oxide as a possible early retrograde messenger. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 11285-11289.
198. Shibuki, K.; Okada, D. Endogenous nitric oxide release required for long-term synaptic depression in the cerebellum. Nature 1996, 349, 326-328.
199. Malen, P. L.; Chapman, P. F. Nitric oxide facilitates long-term potentiation, but not long-term depression. J. Neurosci. 1997, 17, 2645-2651.
200. Steiner, J. P.; Dawson, T. M.; Fotuhi, M.; Snyder, S. H. Immunophilin regulation of neurotransmitter release. A fol. Med. 1996, 2, 325-333.
201. Snyder, S. H.; Sabatini, D. M.; Lai, M. M.; Steiner, J. P.; Hamilton, G. S.; Suzdak, P. D. Neurol actions of immunophilin ligands. Trends Pharmacol. Sci. 1998, 19, 21-26.
202. The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) andcyclosporin for immunosuppression in liver transplantation. N. Engl. J. Med. 1994, 331, 1154-1155.
203. Mueller, A. R.; Platz, K. P.; Bechstein, W. O.; Schattenfroh, N. Neurotoxicity after orthotopic liver transplantation. A comparison between cyclosporin andFK506. Transplantation 1994, 58, 155-170.
204. Steiner, J. P.; Connolly, M. A.; Valentine, H. L.; Hamilton, G. S.; Dawson, T. M.; Hester, L.; Snyder, S. H. Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive dtugs FK506, rapamycin andcyclosporin A. Nature Med. 1997, 3, 421-428.
205. Hamilton, G. S.; Huang, W.; Connolly, M. A.; Ross, D. T.; Guo, H.; Valentine, H. L.; Suzdak, P. D.; Steiner, J. P. FKBP12binding domain analogues of FK506 are potent, nonimmunosuppressive neurotrophic agents in vitro andpromote recovery in a mouse model of Parkinson's Disease. Bioorg. Med. Chem. Lett. 1997, 7, 1785-1790.
206. For a comprehensive review, see: Hamilton, G. S.; Steiner, J. P. Neuroimmunophilin ligands as novel therapeutics for the treatment of degenerative disorders of the nervous system. Curr. Pharm. Des. 1997, 3, 405-428.
207. Holt, D. A.; Konialian-Beck, A. L.; Oh, H.-J.; Yen, H.-K.; Rozamus, L. W.; Krog, A. J.; Erhard, K. F.; Ortiz, E.; Levy, M. A.; Brandt, M.; Bossard, M. J.; Luengo, J. I. Structure-activity studies of synthetic FKBP ligands as peptidyl-prolyl isomerase inhibitors. Bioorg. Med. Chem. Lett. 1994, 4, 315-320.
208. Wang, G. T.; Lane, B.; Fesik, S. W.; Petros, A.; Luly, J.; Krafft, G. A. Synthesis andFKBP binding of small molecule mimics of the tricarbonyl region of FK506. Bioorg. Med. Chem. Lett. 1994, . , 4, 1161-1166.
209. (209) Steiner, J. P.; Snyder, S. H.; Hamilton, G. S. Inhibitors of rotamase "enzyme activity effective at stimulating neuronal growth. U.S. Patent 5, 696, 135.
210. Dragovich, P. S.; Barker, J. E.; French, J.; Imbacuan, M.; Kalish, V. J.; Kissinger, C. R.; Knighton, D. R.; Lewis, C. T.; Moomaw, E. W.; Parge, H. E.; Pelletier, L. A. K.; Prins, T. J.; Showalter, R. E.; Tatlock, J. H.; Tucker, K. D.; Villafranca, J. E. Structurebased design of novel, urea-containing FKBP12 inhibitors. J. Med. Chem. 1996, 39, 1872-1884.
211. Li, G. S.; Hamilton, W.; Huang, M. A.; Connolly, D. T.; Ross, H.; Guo, H.; Valentine, J. P. Steiner. In vitro and in vivo neurotrophic effects of (N-sulfonyl) and (N-carbamoyl) pipecolate esters. 214th American Chemical Society National Meeting, 1997; Abstract MEDI 183.
212. Steiner, J. P.; Hamilton, G. S.; Ross, D. T.; Valentine, H. L.; Guo, H.; Connolly, M. A.; Liang, S.; Ramsey, C.; Li, J.-H.; Huang, W.; Howorth, P.; Soni, R.; Fuller, M.; Sauer, H.; Nowotnick, A.; Suzdak, P. D. Neurotrophic immunophilin ligands stimulate structural andfunctional recovery in neurodegenerative animal models. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 2019-2024.
213. Valentine, H. L.; Liang, S.; Suzdak, P. D.; Hamilton, G. S.; Steiner, J. P. The neuroimmunophilin ligand GPI 1046 stimulates recovery following sciatic nerve injury. Soc. Neurosci. Abstr. 1997, 677.9.
214. Gold, B. G.; Zeleney-Pooley, M.; Wang, M.-S.; Chaturvedi, P.; Armistead, D. M. A nonimmunosuppressive FKBP-12 ligand increases nerve regeneration. Exp. Neurobiol. 1997, 147, 269-278.
215. Gold, B. G.; Zeleney-Pooley, M.; Wang, M.-S.; Chaturvedi, P.; Armistead, D. M.; McCaffrey, P. G. FKBP ligands speed functional recovery andnerve regeneration in the rat sciatic nerve following oral administration. Soc. Neurosci. Abstr. 1997, 449.12.
216. Strange, P. G. Brain Biochemistry and Brain Disorders; Oxford University Press: Oxford, U.K., 1994.
217. Agid, Y. Parkinson's Disease: pathophysiology. Lancei 1991, 337, 1321-1324.
218. Gerlach, M.; Riederer, P.; Przuntek, H.; Youdim, M. B. MPTP mechanisms of neurotoxicity andtheir implications for Parkinson's Disease. Eur. J. Pharmacol. 1991, 208, 273-286.
219. Davis, G. C.; Williams, A. C.; Markey, S. P.; Ebert, M. H.; Caine, E. D.; Reichert, C. M.; Kopin, I. J. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiat. Res. 1979, 3, 249-254.
220. Langston, J. W.; Ballard, P.; Tetrud, J. W.; Irwin, I. Chronic Parkinsonism in humans due to a product of meperidineanalogue synthesis. Science 1983, 219, 979-980.
221. Steiner, J. P.; Ross, D. T.; Valentine, H. L.; Liang, S.; Guo, H.; Huang, W.; Suzdak, P. D.; Hamilton, G. S. The orally active neuroimmunophilin ligand GPI 1046 promotes structural andfunctional recovery in the mouse MPTP model of Parkinson's Disease. Soc. Neurosci. Abstr. 1997, 677.6.
222. Constantini, L. C.; Chaturvedi, P.; McCaffrey, P.; Deacon, T. W.; Isacson, O. Neuroprotective andregenerative effects of immunophilin ligands in an animal model of Parkinson's Disease. Soc. Neurosci. Abstr. 1997, 573.11.
223. Ross, D. T.; Guo, H.; Howorth, P.; Fuller, M.; Nowotnick, A.; Hamilton, G. S.; Suzdak, P. D.; Steiner, J. P. The novel neuroimmunophilin ligand GPI 1046 stimulates morphological, biochemical, andbehavioral recovery in the rat intranigral 6-OHDA Parkinson's Disease model. Soc. Neurosci. Abstr. 1997, 677.7.
224. Sachs, C.; Jonsson, G. Mechanisms of action of 6-hydroxydopamine. Biochem. Pharmacol. 1975, 24, 1-8.
225. Ungerstedt, U.; Aburthnott, G. W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res. 1970, 24, 485-493.
226. Whitaker-Azmita, P. M.; Peroutka, S. J. The neuropharmacology of serotonin. Ann. N. Y. Acad. Sci. 1990, 600.
227. Agid, Y.; Javoy-Agid, F.; Ruberg, M. Biochemistry of neurotransmitters in Parkinson's Disease. In Movement Disorders 2; Marsden, C. D., Fahn, S., Eds.; Buttenvorths: New York, 1992; pp 160-230.
228. Cross, A. J. Serotonin in Alzheimer-type dementia andother dementing illnesses. Ann. N. Y. Acad. Sci. 1990, 600, 405-417.
229. Mamounas, L. A.; Molliner, M. E. Evidence for dual serotonergic projections to neocortex: axons from the dorsal andmedian raphe nuclei are differentially vulnerable to the neurotoxin p-chloroamphetamine (PCA). Exp. Neurol. 1988, 102, 23-36.
230. Mamounas, L. A.; Müllen, C. A.; O'Hearn, E.; Molliner, M. E. Dual serotonergic projections to forebrain in the rat: morphologically distinct 5-HT axon terminals exhibit differential vulnerability to neurotoxic amphetamine derivatives. J. Comp. Neurol. 1991, 314, 558-586.
231. Mamounas, L. A.; Blue, M. E.; Siuciak, J. A.; Altar, C. A. Brainderived neurotrophic factor promotes the survival andsprouting of serotonergic axons in rat brain. J. Neurosci. 1995, 75, 7929-7939.
232. Liang, S.; Valentine, H. L.; Ross, D. T.; Huang, W.; Suzdak, P. D.; Hamilton, G. S.; Steiner, J. P. Neuroimmunophilin ligands augment serotonin fiber protection following lesions with parachloroamphetamine (PCA). Soc. Neurosci. Abstr. 1997, 677.10.
233. Bartus, R. T.; Dean, R. L.; Beer, B.; Lippa, A. S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1992, 277, 408-417.
234. Hefti, F. Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections. J. Neurosci. 1986, 6, 2155-2162.
235. Guo, H.; Spicer, D. M.; Howorth, P.; Hamilton, G. S.; Suzdak, P. D.; Steiner, J. P.; Ross, D. T. The novel small molecule immunophilin ligand GPI 1046 stimulates cholinergic reinnervation of deafferented hippocampal regions after fimbria-fornix transection. Soc. Neurosci. Abstr. 1997, 677.12.
236. Apfel, S. C.; Arezzo, J. C.; Brownlee, M.; Federoff, H.; Kessler, J. A. Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res. 1994, 634, 7-12.
237. Apfel, S. C.; Arezzo, J. C.; Lipson, L.; Kessler, J. A. Nerve growth factor prevents experimental cisplatin neuropathy. Ann. Neurol. 1992, 31, 76-80.
238. McMahon, S. B.; Priestley, J. V. Peripheral neuropathies andneurotrophic factors: animal models andclinical perspectives. Curr. Opin. Neurobiol. 1995, 5, 616-624.
239. Martinez-Serrano, A.; Lundberg, C.; Horellou, P.; Fischer, W.; Bentlage, C.; Campbell, K; McKay, R. D.; Mallet, J.; Bjorklund, A. CNS-derived neural progenitor cells for gene transfer of nerve growth factor to the adult rat brain: complete rescue of axotomized cholinergic neurons after transplantation into the septum. J. Neurosci. 1995, 15, 5668-5680.
240. Gash, D. M.; Zhang, Z.; Ovadia, A.; Cass, W. A.; Yi, A.; Simmerman, L.; Russell, D.; Martin D.; Lapchak, P. A.; Collins, F.; Hoffer, B. J.; Gerhardt, G. A. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996, 380, 252-255.
241. Woolf, C. J.; Ma, Q. P.; Allchorne, A.; Poole, S. J. Peripheral cell types contributing to the hyperalgesic action of nerve growth factor in inflammation. J. Neurosci. 1996, 16, 2716-2723.
242. Goto, S.; Singer, W. Laminar andcolumnar organization of immunoreactivity for calcineurin, a calcium- andcalmodulin" regulated protein phosphatase, in monkey striate cortex. Cereb. Cortex 1994, 4, 636-645.
243. Ivery, M. T.; Weiler, L. Modeling the interaction between FK506 andFKBP12: a mechanism for the formation of the calcineurin inhibitory complex. Bioorg. Med. Chem. 1997, 5, 217-232.
244. Wang, M. S.; Zeleny-Pooley, M.; Gold, B. G. Comparative dosedependency study of FK506 andcyclosporin A on the rate of axonal regeneration in rat sciatic nerve. J. Pharmacol. Exp. Ther. 1997, 282, 1084-1093.
245. Boriongan, C. V.; Stahl, C. E.; Fujisaki, T.; Porter, L. L.; Wtanabe, S. Cyclosporine A inhibits calcineurin activity andinduces nigral dopamine neurite outgrowth, but does not impair memory retention in rats with damaged blood brain barrier. Soc. Neurosci. Absir. 1998, 778.16.